Literature DB >> 4557736

Clinical experiences with the streptococcal anticancer preparation, OK-432 (NSC-B116209).

T Kurokawa, T Hattori, H Furue.   

Abstract

Mesh：

Substances：

Year:  1972        PMID： 4557736

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  5 in total

1.  Treatment of gastric cancer, with special reference to the survivals of the cancer patients treated with multiple combination MFC therapy or immunochemotherapy of MFC plus OK-432 (NSC B116209).

Authors:  S Suga; H Tsunekawa; M Washino; N Makino; Z Tamura; S Goto
Journal:  Gastroenterol Jpn       Date:  1977

2.  Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.

Authors:  H Wakasugi; K Oshimi; M Miyata; Y Morioka
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

3.  Intrauterine therapy for macrocystic congenital cystic adenomatoid malformation of the lung.

Authors:  Jin-Young Min; Hye-Sung Won; Mi-Young Lee; Hye-Jin Suk; Jae-Yoon Shim; Pil-Ryang Lee; Ahm Kim
Journal:  Obstet Gynecol Sci       Date:  2014-03-15

4.  Clinical studies on streptococcal preparation (OK-432) combined with mitomycin-C, 5-FU and cytosine arabinoside in advanced cancer patients.

Authors:  T Hattori; M Nimoto; S Yamagata; T Tohge
Journal:  Jpn J Surg       Date:  1975-09

5.  Treatment of lymphangiomas by means of sclerotherapy with OK-432 (Picibanil®) is safe and effective - A retrospective case series.

Authors:  G Fasching; C Dollinger; S Spendel; N F Tepeneu
Journal:  Ann Med Surg (Lond)       Date:  2022-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.